Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064604 | 0.95 | FFAR1 (0.51) | FFAR1FFAR4ALDH1A1TSHRCMKLR1 | |
| SCHEMBL3012667 | 0.90 | FFAR1 (0.48) | FFAR1FFAR4ALDH1A1TSHRPOLB | |
| SCHEMBL2975161 | 0.90 | FFAR1 (0.42) | FFAR1FFAR4ALDH1A1TSHRLTB4R | |
| SCHEMBL2965353 | 0.89 | FFAR1 (0.49) | FFAR1FFAR4ALDH1A1TSHRTDP1 | |
| SCHEMBL3036279 | 0.89 | FFAR1 (0.49) | FFAR1FFAR4ALDH1A1TSHRCMKLR1 | |
| SCHEMBL10064434 | 0.88 | FFAR1 (0.45) | FFAR1FFAR4ALDH1A1TSHRCMKLR1 | |
| SCHEMBL2975821 | 0.88 | FFAR1 (0.46) | FFAR1FFAR4ALDH1A1TSHRCMKLR1 | |
| SCHEMBL2947118 | 0.88 | FFAR1 (0.48) | FFAR1FFAR4ALDH1A1TSHR | |
| SCHEMBL2970621 | 0.88 | FFAR1 (0.53) | FFAR1FFAR4ALDH1A1TSHR | |
| SCHEMBL2968632 | 0.86 | FFAR1 (0.44) | FFAR1FFAR4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| WO-2012004270-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | REN, PKD1, AKR1C3 | FFAR1 287/4885FFAR4 845/4885ALDH1A1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.